Ex-Pfizer head joins Red Door as International director
pharmafile | September 10, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Andrew Thomas, Pfizer, Red Door
Andrew Thomas the strategic communications lead for Pfizer’s primary care medicines across Europe and Canada joins Red Door Communications in September as head of International.
Thomas has 12 years’ experience delivering proactive communications and media relations programmes and managing reactive issues at domestic, pan-European and global levels both within agency and in-house.
Prior to joining RDC, his role at Pfizer was communications lead for a portfolio that included some of the company’s highest profile medicines. He also led on the response to numerous national and regional media issues and worked closely with European business unit leadership, in-country communicators and New York colleagues.
Catherine Warne, head of Creston Health said: “I have known Andrew for many years as a competitor and then a client. He is great fun, hugely well-liked and respected in our industry and a proven influencer at a senior level. We are very excited that he is joining us and believe he is the ideal person to drive our international business.”
Thomas added: “My time at Pfizer required me to work across complex organisational structures and to understand what works, what doesn’t work and, most importantly, why that is the case. Success in that role was ultimately predicated on an ability to build, maintain and cultivate effective relationships based on trust and shared ownership with internal and external stakeholders alike.
“I believe those skills mean I will be able to make a real contribution to the Red Door Communications team and help develop their existing international offering still further.”
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
